OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
48
Results
Show all
Save search
Copy query
Show results for
Unknown
(48)
Publication Date
Release Date
2021
(8)
2020
(6)
2023
(5)
2022
(5)
2015
(5)
2025
(4)
2018
(3)
2024
(2)
2019
(2)
2017
(2)
2014
(2)
2012
(2)
2013
(1)
2011
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V.
Not available
S-EPMC5762688
|
biostudies-literature
Cite
Crystal, solution and in silico structural studies of dihydrodipicolinate synthase from the common grapevine.
Not available
S-EPMC3382604
|
biostudies-literature
Cite
Protocol for implementation of the 'AusPROM' recommendations for elective surgery patients: a mixed-methods cohort study.
Not available
S-EPMC8449982
|
biostudies-literature
Cite
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
BRAF
V600-Mutant Stage III Melanoma.
Not available
S-EPMC6286159
|
biostudies-literature
Cite
C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking.
Not available
S-EPMC4049310
|
biostudies-literature
Cite
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
Not available
S-EPMC7682474
|
biostudies-literature
Cite
ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1.
Not available
S-EPMC4979432
|
biostudies-literature
Cite
Body Mass Index, sex, non-steroidal anti-inflammatory drug medications, smoking and alcohol are differentially associated with World Health Organisation criteria and colorectal cancer risk in people with Serrated Polyposis Syndrome: an Australian case-control study.
Not available
S-EPMC9701413
|
biostudies-literature
Cite
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Not available
S-EPMC7676886
|
biostudies-literature
Cite
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Not available
S-EPMC5396114
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets